LDS/Medical Tests/Neurofibromatosis Type 1 (NF1) Gene Mutation Analysis

Neurofibromatosis Type 1 (NF1) Gene Mutation Analysis

Neurofibromatosis Type 1 (NF1) also known as von Recklinghausen disease or peripheral neurofibromatosis, is a neurocutaneous condition characterized by changes in skin pigmentation and the growth of tumors along nerves in the skin, brain, eyes, and other parts of the body. It is characterized by multiple café-au-lait spots, axillary and inguinal freckling, multiple cutaneous neurofibromas, and iris Lisch nodules and choroidal freckling. Patients with NF1 are also at increased risk for various malignancies, including malignant peripheral nerve sheath tumors, optic and CNS gliomas, and gastrointestinal stromal tumors (GIST). There is also an increased risk of adult-onset breast cancer in women. Neurofibromatosis type 1 occurs in 1 in 3,000 to 4,000 people worldwide.

NF1 is an autosomal dominant disorder caused by the mutations of the NF1 gene on chromosome at 17q11.2 that encodes for neurofibromin. This protein is produced in many cells, including neurons and specialized cells that surround nerves (oligodendrocytes and Schwann cells). Haploinsufficiency, due to germline NF1 gene mutations, is believed to account for the neurocognitive defects seen with the disorder while further somatic mutation or loss of heterozygosity at the NF1 locus results in tumorigenesis. The diagnosis of NF1 is usually based on clinical findings. However, identification of heterozygous pathogenic variants in NF1 by molecular genetic testing can confirm a diagnosis.

  • Diagnostic confirmation of Neurofibromatosis Type 1
  • Prenatal diagnosis for known familial mutation(s) in at-risk pregnancies.
  • Early diagnosis and management of disease
Any heterozygous mutation or pathogenic variant in NF1gene is consistent with Neurofibromatosis type 1. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants.

Negative for mutation or pathogenic variant in NF1 gene

Sequence analysis by next generation sequencing or bi-directional sequencing of the entire coding region and intron-exon boundaries of the NF1 gene. NF1 gene-targeted deletion/duplication analysis detects intragenic deletions or duplications. Methods that may be used include quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a gene-targeted microarray designed to detect single-exon deletions or duplications.

Whole blood (EDTA).

Stability

  • Ambient: 3-5 days
  • Refrigerated: 7-14 days
  • Frozen: Unacceptable
Skin biopsy, Solid tumor gene mutation panel, NGS.
1-2 weeks.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • J Med Genet. 1996; 33: 2–17. [PMID: 8825042]
  • Brain Pathol. 1995 Apr;5(2):153-62. [PMID: 7670656]
  • Hum Pathol. 2017;67: 1-10. [PMID: 28551330]
  • Acta Derm Venereol. 2014;94:663-6. [PMID: 24676424]
  • Semin Pediatr Neurol. 2006;13: 8-20. [PMID: 16818171]
  • J Child Neurol. 2002;17: 592-601. [PMID: 12403558]
  • GeneReviews® [Internet]. Available at: https://www.ncbi.nlm.nih.gov/books/NBK1109/
  • Genetics Home Reference. Available at: https://ghr.nlm.nih.gov/condition/neurofibromatosis-type-1#
  • Genetics Home Reference. Available at: https://ghr.nlm.nih.gov/gene/NF1#